AbCellera Biologics Inc. (NASDAQ: ABCL) reported positive interim Phase 1 clinical trial results for ABCL635, an experimental antibody treatment for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE